Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Titel:
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Auteur:
Infante, Jeffrey R. Patnaik, Amita Verschraegen, Claire F. Olszanski, Anthony J. Shaheen, Montaser Burris, Howard A. Tolcher, Anthony W. Papadopoulos, Kyriakos P. Beeram, Muralidhar Hynes, Scott M. Leohr, Jennifer Lin, Aimee Bence Li, Lily Q. McGlothlin, Anna Farrington, Daphne L. Westin, Eric H. Cohen, Roger B.